avoparcin and Swine-Diseases

Prevalence of vancomycin-resistant enterococci (VRE) was investigated in Korean livestock 4 years after the ban of avoparcin in feed additives. VRE were isolated from approximately 16.7% of the chicken samples (57 strains from 342 meat samples) and 1.9% of the pig samples (4 from 214 fecal samples). No VRE, however, was isolated from 110 bovine fecal samples. All the 61 VRE isolates were vanA-type Enterococcus faecium expressing a high-level resistance to vancomycin, and showed resistance to teicoplanin as well except two poultry isolates. In addition, the VRE isolates had heterogeneous pulsed-field gel electrophoresis (PFGE) patterns of SmaI-digested DNA, although identical or closely related profiles were observed among strains isolated from the same farm. Although the chicken isolates were all poultry type with G at position 8,234 of the vanX gene, the pig isolates were all swine type with T at position 8,234 of the vanX gene.

Topics: Animal Feed; Animals; Animals, Domestic; Anti-Bacterial Agents; Bacterial Proteins; Cattle; Cattle Diseases; Chickens; Electrophoresis, Gel, Pulsed-Field; Enterococcus faecium; Feces; Food Microbiology; Glycopeptides; Gram-Positive Bacterial Infections; Korea; Meat; Mutation; Poultry Diseases; Serine-Type D-Ala-D-Ala Carboxypeptidase; Swine; Swine Diseases; Vancomycin Resistance

Glycopeptide resistant enterococci (GRE) isolated from animals and humans were characterised using both AFPL typing and genetic characterisation of the glycopeptide resistance transposon Tn1546. All isolates were collected in 1997 when the glycopeptide avoparcin was still being used as growth promoter. All investigated animal isolates were from mixed pig and poultry farms in the Netherlands and the human isolated from the farmers of these farms. A total of 24 isolates were investigated. AFLP and Tn1546 typing revealed that both pig and poultry related enterococcal and vanA transposon genotypes were found among the human isolates indicating spread of glycopeptide resistance from both pig and poultry to the farmers. These findings contradict previous finding that showed that GRE recovered from the general population were genotypically undistinguishable from GRE isolated from pigs but are in line with other studies that demonstrated spread of GRE from poultry to farmers in poultry farms.

Topics: Agriculture; Animals; Anti-Bacterial Agents; Chickens; DNA, Bacterial; Enterococcus; Feces; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Netherlands; Phylogeny; Polymerase Chain Reaction; Poultry Diseases; Swine; Swine Diseases; Vancomycin Resistance

The aim of this study was to evaluate the effect of different antibiotics used as growth promoters on the control of porcine intestinal adenomatosis when administered in weaning, growing and fattening pig diets, according to Annex I of the European Union directive (70/524/EEC and its subsequent amendments to date) for the use of feed additives. On a farm with a previous history of proliferative enteropathy outbreaks, 648 weaned piglets (23 days old) were divided into nine experimental groups according to bodyweight and sex ratio, each group comprising four pens with 18 pigs in each pen. One group served the trial as a negative (unmedicated) control: another (the positive control) received monensin via feed at 100 p.p.m. up to the end of the growing phase (107 days old) and 50 p.p.m. up to slaughter age (156 days old). The remaining seven groups were offered feed with the addition of the following antibiotics: virginia-mycin (50-20 p.p.m.), avilamycin (40-20 p.p.m.), spiramycin (50-20 p.p.m.), zinc bacitracin (50-10 p.p.m.), avoparcin (40-20 p.p.m.), tylosin (40-20 p.p.m.) and salinomycin (60-30 p.p.m.), respectively. The performance of the pigs in the positive control group was very satisfying and among the highest in the trial, verifying earlier field studies. As a general conclusion it seems that all tested growth promoters had a beneficial effect compared with the untreated control, indicated by the decrease of mortality rate, the elimination of diarrhoeal incidence and the enhancement of growth performance, although the proliferative enteropathy control achieved by each substance was not always satisfactory. More specifically, the antibiotic growth promoters tested can be scaled according to their total efficacy as follows: 1. Salinomycin, tylosin, spiramycin; 2. Virginiamycin, zinc bacitracin, avilamycin; and 3. Avoparcin. Finally, it is considered that part of the growth promotion efficacy of the tested substances is due to their potential capacity to control porcine intestinal adenomatosis; thus, in future growth performance trials, the disease background of the trial farms must be examined, especially for porcine enteropathy challenges.

Topics: Abattoirs; Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacitracin; Bacterial Infections; Disease Outbreaks; Female; Food, Fortified; Glycopeptides; Greece; Growth Substances; Ileitis; Ileum; Intestinal Mucosa; Male; Monensin; Oligosaccharides; Pyrans; Spiramycin; Swine; Swine Diseases; Tylosin; Virginiamycin

We determined the association between the use of the glycopeptide antibiotic avoparcin as a growth promoter and the occurrence of Enterococcus faecium (VREF) with high-level resistance to vancomycin (MIC > or = 64 micrograms ml-1) on poultry and pig farms. The investigations were conducted as retrospective cohort studies, where groups of farms exposed or not exposed to avoparcin between September 1994 and April 1995 were compared. In poultry, the association between the use of avoparcin and the occurrence of VREF was confounded by the use of broad-spectrum antibiotics, and the adjusted relative risk was 2.9 (1.4-5.9). In pigs, the association had a similar magnitude with a non-adjusted relative risk of 3.3 (0.9-12.3). The similar findings in the two studies provide evidence in favour of a causal association between the use of avoparcin and the occurrence of VREF on farms, and suggest that food animals constitute a potential reservoir of infection for VREF in humans.

Topics: Animals; Anti-Bacterial Agents; Antibodies, Bacterial; Chickens; Cohort Studies; Denmark; Disease Susceptibility; Drug Resistance, Microbial; Enterococcus faecium; Female; Glycopeptides; Gram-Positive Bacterial Infections; Growth Substances; Male; Poultry; Poultry Diseases; Retrospective Studies; Specific Pathogen-Free Organisms; Swine; Swine Diseases; Vancomycin